Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
BYBeyondSpring Inc. logo

BeyondSpring Inc. (BYSI)

NASDAQ Capital Market · Currency in USD
$0.43 ▲ +0.00 (+0.05%)
As of Oct 26, 11:36 AM ET. Market open.

Summary

Previous Close
$0.43
Open
$0.43
Day's Range
$0.43 – $0.52
52 Week Range
$0.42 – $2.44
Volume
12,198
Avg. Volume
23,677
Market Cap
$17.73M
Beta (5Y Monthly)
0.43
PE Ratio (TTM)
--
EPS (TTM)
-$0.16
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: BeyondSpring Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
44
CEO
Qiu Min

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.54 · Revenue est. $8.77M
DateEst.Actual
Aug 14, 2026-$0.54-$0.02Beat
May 13, 2026-$0.54-$0.05Beat
Mar 25, 2026-$0.54-$0.05Beat
Nov 12, 2025–-$0.05
Aug 13, 2025–-$0.04
May 12, 2025–-$0.06

Analyst view

Rating: Buy
Buy 67% · Hold 22% · Sell 11%

Get free alerts on BYSI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.